Loading...
•
Sep 30, 2023
Onconova Q3 2023 Earnings Report
Reported third quarter 2023 financial results and provided a pipeline progress update.
Key Takeaways
Onconova Therapeutics reported its third quarter 2023 financial results, highlighting progress with narazaciclib and rigosertib, and provided updates on partnering opportunities and key personnel appointments. The company's cash and cash equivalents were reported as $25.2 million.
Advanced registrational trial preparations for narazaciclib in low grade endometrioid endometrial cancer (LGEEC).
Observed clinical and biological target engagement with narazaciclib and an acceptable safety profile in the Phase 1/2 program.
Progressed the development of a registrational study plan for rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB-associated SCC).
Appointed Dr. Victor Moyo as Chief Medical Officer and Meena Arora as Vice-President, Global Medical Affairs & Research and Development.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...